Get CME Credits

Creators:

Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD) and the Desmoid Tumor Research Foundation (DTRF)

Availability:

Program Expired:  December 12, 2024

Access Program

Description:

Desmoid tumors are challenging to manage due to the difficulty obtaining an accurate diagnosis and the scarcity of treatment options. Despite the benefits seen with tyrosine kinase inhibitors, there are no FDA-approved therapies yet for treatment of desmoid tumors. However, emerging therapies are showing clinical benefit and have the potential to improve the treatment armamentarium. 

Join a panel of experts to discuss the best strategies to improve timely diagnoses of patients with desmoid tumors. Experts will review the recent shift away from extensive surgery to active surveillance and explore emerging treatments that have demonstrated promising results for patients with progressive disease. Panelists will also discuss the need for multidisciplinary review to determine if treatment is warranted and examine which patients are eligible for treatment with emerging options. 

Learning Objectives:

• Apply relevant strategies to address timely diagnosis in patients with desmoid tumors
• Discuss patient selection for treatment based on safety and efficacy data

Topics of Interest:

• Impact of misdiagnoses on outcomes with desmoid tumors
• Practical strategies to improve diagnostic accuracy
• Treatment burden and patient quality of life
• Conventional treatment approaches
• Gamma secretase inhibitors
• Where do emerging agents fit in the timeline? 
• Role of the multidisciplinary team in care
• Special considerations for adolescent and young adult (AYA) patients 
• Counseling patients about clinical trials, resources, and patient organizations

Top Faculty/ KOLs:

Mrinal Gounder, MD

Associate Attending Professor

Sarcoma Oncologist & Early Phase Drug Development Specialist

Memorial Sloan Kettering Cancer Center

Richard F. Riedel, MD

Associate Professor of Medicine with Tenure

Associate Director, Duke Sarcoma Center

Duke Cancer Institute

Duke University

ACKNOWLEDGEMENT

This activity is supported by an independent educational grant from SpringWorks Therapeutics, Inc. 

DATE OF LIVE ACTIVITY

This activity was released on December 12, 2023 and is valid for 12 months. Requests for credit must be made no later than December 12, 2024.

TARGET AUDIENCE 

The educational design of this activity addresses the needs of sarcoma specialists, medical oncologists, and other members of the care team for desmoid tumors.

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT 

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. 

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media. 

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

The planners and managers at Global Education Group have no relevant financial relationships to disclose. 

The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose. 

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Physician Accreditation Support:

For information about the physician accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com. 

Creators:

PeerView & the DTRF (Made possible with support from SpringWorks Therapeutics)

Availability:

Expired November 26, 2024

Access Program

Mediums:

The PeerView inQuiry presentation can be downloaded in MP3 format, and the entire program is available as a podcast via the PeerView channels on Apple Podcasts, Spotify, TuneIn, Google Podcasts, and Amazon Alexa. The podcasts and online media player are fully compatible with all mobile devices. Furthermore, all the slides are easily downloadable as a PowerPoint slide kit.

Description:

Until recently, ICD-10-CM codes for desmoid tumors (DTs) were broadly defined, creating a significant impediment to research efforts. Through a didactic expert-led discussion, get to know the new ICD-10-CM codes for desmoid tumors and learn how to navigate these codes more efficiently as a healthcare provider or researcher in this new question-based activity that lets you earn your CME credit as you go.

This educational program leverages microlearning through question-based segments to help clinicians better navigate the variable presentations of desmoid tumors and the new ICD-10-CM codes. Throughout the program, two leading experts address gaps and barriers that affect healthcare providers, patients, and researchers by offering practical guidance on current evidence-based diagnostic strategies, describing the new desmoid tumor–specific ICD-10-CM codes, and detailing the new codes’ implications for clinical practice, patient care, and research. In addition to these question-based segments, downloadable Practice Aids and additional resources for clinicians and patients are available.

Upon completion of this activity, participants should be better able to:

• Discuss the gaps and barriers in the diagnosis and treatment of desmoid tumors (DTs), including the prior lack of DT-specific ICD-10-CM codes
• Characterize the details of the new DT-specific ICD-10-CM codes, including the subcategories for tumor locations
• Implement best practices for integrating the new DT-specific ICD-10-CM codes in clinical and research settings
• Employ the latest recommendations for establishing an accurate diagnosis and assigning the correct ICD-10-CM codes to patients with DTs to guide further care decisions

Creators:

PeerView Institute for Medical Education (PVI) & the Desmoid Tumor Research Foundation (DTRF) (Made Possible with support from SpringWorks Therapeutics)

Availability:

Expired February 22, 2024.

Access Program

Description:

Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors.

This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions.

This PeerView program is chaired and presented by Ravin Ratan, MD, M.Ed from the MD Anderson Cancer Center. Dr. Ratan is joined on the faculty by Christina L. Roland, MD, MS, FACS, from MD Anderson Cancer Center and desmoid tumor patient, Kathleen Hodgkins.

Upon completion of this activity, participants should be better able to:

• Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors
• Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors
• Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences

Activity Release Date: November 30, 2022
Activity Expiration Date: December 29, 2023
Time to Complete Activity: 60 minutes

Access Program

IMPORTANT NOTE:  This activity expired on December 29, 203; credit is no longer available.

Activity Description

The management of patients with desmoid tumors is currently transitioning from surgical approaches to more conservative strategies by utilizing systemic therapy. The discovery that desmoid tumors are almost universally associated with genetic alterations in the Wnt/β-catenin pathway has provided rationale for the development of gamma secretase inhibitors (GSIs), a new promising class of agents, and several are in late-phase testing. Although no systemic therapies have received regulatory approval for the treatment of desmoid tumors to date, it is important to be prepared to learn how to integrate GSIs into practice.

This PeerView educational activity, based on a recent live symposium, features a panel of leading experts in managing patients with desmoid tumors. The faculty provide expert insights and practical guidance for navigating the latest treatment advances, including GSIs, for desmoid tumors. In addition, illustrative cases and clinical scenarios are discussed to demonstrate the emerging role and integration of novel GSIs in real-world patient care settings.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, general surgeons, advanced practice clinicians, and other healthcare professionals involved in the care of patients with desmoid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of adult and pediatric desmoid tumors
• Implement validated strategies that harness multidisciplinary team-based approaches to diagnose desmoid tumors, including referring patients to sarcoma specialists
• Integrate novel therapeutic approaches based on current evidence to include emerging therapies in the context of clinical trial enrollment into the treatment plans of patients with desmoid tumors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Bernd Kasper, MD, PhD
Associate Professor
University of Heidelberg
Mannheim Cancer Center (MCC)
Sarcoma Unit
Mannheim, Germany

Bernd Kasper, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ayala Pharmaceuticals; Bayer AG; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; PharmaMar; and SpringWorks Therapeutics.
Other Financial or Material Support as Chair of the EORTC Soft Tissue and Bone Sarcoma Group.

Faculty/Planner
Mrinal Gounder, MD
Associate Professor
Sarcoma Medical Oncology | Early Drug Development (Phase I)
MSK Physician Ambassador – India and Asia
Memorial Sloan Kettering Cancer Center
New York, New York

Mrinal Gounder, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ayala Pharmaceuticals; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; SpringWorks Therapeutics; and TYME Inc.
Grant/Research Support from Ayala Pharmaceuticals; Bayer AG; Iterion Therapeutics; and SpringWorks Therapeutics.
Speakers Bureau participant with Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; and Karyopharm Therapeutics.

Faculty/Planner
Alessandro Gronchi, MD
Surgical Oncologist
Chair Sarcoma Service
Head of the Department of Surgery
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy

Alessandro Gronchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer AG; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; PharmaMar; and SpringWorks Therapeutics.
Grant/Research Support from Nanobiotix and PharmaMar.
Speakers Bureau participant with Deciphera Pharmaceuticals, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Desmoid Tumor Research Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView